EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening

Exact Sciences (EXAS) recently received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus. This marks a significant advancement for the company in the field of colorectal cancer (CRC) screening.This approval solidifies the company's leadership in the non-invasive cancer diagnostics space, offering a more accurate tool to combat one of the most preventable, yet often overlooked, cancers in the United States.EXAS' Cologuard Plus Raises the Bar in CRC ScreeningThe FDA approval was ...